Skip to Content

Data on VIVUS' Qnexa to be Presented at European Congress Focused on Cardiovascular Prevention and Rehabilitation

Update: Qsymia (phentermine/topiramate) Now FDA Approved - July 17, 2012



MOUNTAIN VIEW, Calif., May 5 /PRNewswire-FirstCall/ -- VIVUS, Inc. (NASDAQ:VVUS) today announced that new data on Qnexa®, an investigational drug candidate, will be presented at EuroPRevent 2010, the annual congress of the European Association for Cardiovascular Prevention and Rehabilitation, organized by the European Society of Cardiology, in Prague, Czech Republic. Kishore Gadde, MD, director of obesity clinical trials at Duke University and a lead investigator, will make two presentations based on the results of the CONQUER (OB-303) study, which studied the effects of Qnexa on overweight or obese patients with two or more co-morbidities over 56 weeks. On May 6, Dr. Gadde will make a poster presentation entitled, "12-Month Weight Loss and Antihypertensive Benefits With PHEN/TPM CR in Overweight and Obese Subjects With Hypertension," followed by a moderated poster presentation on May 7 entitled, "12-Month Weight Loss and Triglyceride Changes With PHEN/TPM CR in Overweight and Obese Subjects With Hypertriglyceridemia."

"We are thrilled to be sharing the Qnexa hypertension and lipid clinical data with our medical and industry colleagues in Europe at this prestigious congress," stated Peter Tam, president, VIVUS. "Earlier in the week, Dr. Oparil shared the pooled antihypertensive 28-week Qnexa data with her cardiology colleagues at the American Society of Hypertension. Dr. Gadde's presentations at EuroPRevent 2010 will feature data highlighting the effects of Qnexa on weight-related co-morbidities with our colleagues in Europe. We look forward to being a part of this and other key clinical meetings."

Following are details about the upcoming presentations:

EuroPRevent 2010, the Annual Congress of the European Association for Cardiovascular Prevention and Rehabilitation, Hilton Prague, Prague, Czech Republic

  Date and Time: Thursday, May 6, 2010, 10:00-11:00 AM
  Session Title: Prevention & Health Policy
  Presentation Title: 12-Month Weight Loss and Antihypertensive Benefits
   With PHEN/TPM CR in Overweight and Obese Subjects With Hypertension
  Abstract: 10666
  Poster: 311
  Location: Poster Area
  Presenter: Kishore Gadde, MD

  Date and Time: Friday, May 7, 2010, 8:30 AM
  Session: Poster Session 3: Prevention and Health Policy: Obesity,
   Nutrition and Health Services
  Presentation Title: 12-Month Weight Loss and Triglyceride Changes With
   PHEN/TPM CR in Overweight and Obese Subjects With
  Abstract: 10664
  Poster: 303
  Location: Poster Area
  Presenter: Kishore Gadde, MD

  About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2009 and periodic reports filed with the Securities and Exchange Commission.


  VIVUS, Inc.             Investor Relations: The Trout Group
  Timothy E. Morris                           Brian Korb
  Chief Financial Officer                     646-378-2923
                          Media Relations:    Pure Communications, Inc.
                                              Dan Budwick

Source: VIVUS, Inc.

CONTACT: VIVUS, Inc., Timothy E. Morris, Chief Financial Officer,
+1-650-934-5200; or Investor Relations: The Trout Group, Brian Korb,
+1-646-378-2923; or Media Relations: Pure Communications, Inc., Dan Budwick,

Web Site:

Posted: May 2010